Home
Race Oncology Ltd
Pre-IND Meeting Confirms 505(b)(2) Pathway for Bisantrene
Business
Feb 16 2017
4 min read

Pre-IND Meeting Confirms 505(b)(2) Pathway for Bisantrene

news images

Race Oncology Ltd has released a press release.

View Attachment